- Home
- LWLG vs PBYI Comparison
LWLG vs PBYI Comparison
Compare LWLG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- PBYI
- Stock Information
- Founded
- LWLG 1991
- PBYI 2010
- Country
- LWLG United States
- PBYI United States
- Employees
- LWLG N/A
- PBYI N/A
- Industry
- LWLG Containers/Packaging
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LWLG Industrials
- PBYI Health Care
- Exchange
- LWLG Nasdaq
- PBYI Nasdaq
- Market Cap
- LWLG 126.0M
- PBYI 138.4M
- IPO Year
- LWLG N/A
- PBYI N/A
- Fundamental
- Price
- LWLG $0.93
- PBYI $2.86
- Analyst Decision
- LWLG
- PBYI Strong Buy
- Analyst Count
- LWLG 0
- PBYI 1
- Target Price
- LWLG N/A
- PBYI $7.00
- AVG Volume (30 Days)
- LWLG 869.4K
- PBYI 334.3K
- Earning Date
- LWLG 05-09-2025
- PBYI 05-01-2025
- Dividend Yield
- LWLG N/A
- PBYI N/A
- EPS Growth
- LWLG N/A
- PBYI 37.78
- EPS
- LWLG N/A
- PBYI 0.62
- Revenue
- LWLG $95,605.00
- PBYI $230,468,000.00
- Revenue This Year
- LWLG N/A
- PBYI N/A
- Revenue Next Year
- LWLG N/A
- PBYI N/A
- P/E Ratio
- LWLG N/A
- PBYI $4.61
- Revenue Growth
- LWLG 136.05
- PBYI N/A
- 52 Week Low
- LWLG $0.79
- PBYI $2.23
- 52 Week High
- LWLG $4.36
- PBYI $5.34
- Technical
- Relative Strength Index (RSI)
- LWLG 41.03
- PBYI 42.27
- Support Level
- LWLG $0.87
- PBYI $2.83
- Resistance Level
- LWLG $1.05
- PBYI $2.99
- Average True Range (ATR)
- LWLG 0.10
- PBYI 0.17
- MACD
- LWLG 0.01
- PBYI -0.01
- Stochastic Oscillator
- LWLG 35.00
- PBYI 50.00
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.